WBDR HTC Funding Program

The World Bleeding Disorders Registry (WBDR) HTC Funding Program (HFP) is designed to provide funds to support data collection activities at WBDR HTCs in low and lower-middle income countries.

The Program aims to help HTCs improve patient enrolment, the recording of follow-up visits, and the use of functional scales and the Quality of Life questionnaire.

APPLICATION CYCLE

Submission of complete application formOctober 30, 2025
Announcement of recipientsDecember 2025
Funds disbursedDecember 2025
Training sessionsJune 2026

CRITERIA

ELIGIBILITY

The applying HTC must meet all of the following:

  • Be in a low or lower-middle income country according to the current World Bank’s GNI classification
  • Have obtained, and shared with the WBDR team, an ethics approval letter to participate in the WBDR. If the HTC is in the process of obtaining ethics approval, and meets all the other criteria, the application will be reviewed upon receipt of the ethics approval.
  • Have received training on the WBDR online database
  • Commit to attending the annual WBDR Data Entry Refresher training

FUNDING

Eligible HTCs will be compensated based on the number of active hemophilia and VWD patients enrolled in the WBDR or the number of identified hemophilia and VWD patients being followed at the HTC at the time of the application.

The funds are allocated for a period of one year and will be disbursed in one installment.

TERMS AND CONDITIONS

CHANGE IN THE RECIPIENT'S STATUS

The funding recipient must contact the WFH to describe any significant changes in the recipient’s circumstances that might affect the use of funds. The WFH must also be notified of any changes in institutional affiliation. The transfer of funds to another institution or investigator will be at the sole discretion of the WFH.

EXPENSES

The funds should be used only for expenses related to WBDR activities.

DISBURSEMENT OF FUNDS

The WFH must receive all required documents before the payment is transferred. The funding will be disbursed in one payment to the hosting institution.

FUNDS

The amount of funding per HTC is determined according to a three-category scheme and is based on the number of hemophilia and VWD patients enrolled in the WBDR or identified at the HTC at the time of the application. Those numbers are re-evaluated upon a request for funding renewal.

Upon receipt of payment, the recipient must send a statement from their institution confirming the receipt of the funds.

PROGRESS

Recipient HTCs are required to complete a Funding Report where they indicate what the funds were used for.

Additionally, an internal evaluation based on the data entry performance in the WBDR will be conducted to assess the eligibility of the HTC for renewal. The Program aims to help HTCs improve patient enrolment, reporting of follow-up visit data, and use of functional scales and the Quality of Life questionnaire.

TERMINATION OF SUPPORT

The WFH reserves the right to terminate support of the project at any time and for any reason at its sole discretion.

APPLICATION PROCESS

All submissions are reviewed by the WBDR team and HTCs that fit the eligibility criteria will be invited to attend the required training. Completed applications must be sent by email to [email protected].

Please read the criteria and conditions before submitting an application.

Download the WBDR HTC Funding Program 2024 Application Form:

For more information, contact [email protected].

Did you know?

The WFH supports and empowers patient leaders and healthcare professionals worldwide by offering national, regional, and global training programs and initiatives.

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.